Shanghai Securities News China SecuritiesNet News (Reporter Sun Zhong) Walvax BioAn announcement on the 29th stated that the 13-valent pneumococcal polysaccharide conjugate vaccine produced by its subsidiary Yuxi Walvax recently received a "Drug Registration Certificate" issued by the Jordan Food and Drug Administration.
　　The Yuxi Walvax 13-valent pneumococcal polysaccharide conjugate vaccine is mainly suitable for vaccination of infants and children aged 6 weeks to 5 years (before the age of 6 years). It is used to prevent infectious diseases caused by the 13 serotypes of pneumococcus contained in this vaccine (type 1, type 3, type 4, type 5, type 6A, type 6B, type 7F, type 9V, type 14, type 18C, type 19A, type 19F and type 23F). The vaccine was approved for sale in China in 2020.
　　Currently, pneumococcal infection remains one of the leading causes of death in children under five worldwide. In Jordan, this infection also poses a serious health threat to infants and young children. An analysis of 1,015 cases of pneumococcal infection in children under five showed that 1,006 of them were pneumonia cases, with the most common serotypes being 6B (16.45%), 6A (13.60%), 14 (12.12%), and 19F (8.18%). The Jordanian government prioritizes childhood immunization and has incorporated pneumococcal conjugate vaccine into its national immunization program.
　　Receiving Jordan's Drug Registration Certificate marks a key advancement in the company's strategic expansion into the Middle East market and a significant breakthrough in the internationalization of its 13-valent pneumococcal polysaccharide conjugate vaccine. As this is the first time the company's product has been approved for market entry in Jordan, there remains some uncertainty regarding the vaccine's actual launch date and sales performance. The company will actively advance related work and fulfill its information disclosure obligations in a timely manner.
https://finance.eastmoney.com/a/202509293526576541.html